Royal Bank of Canada grew its holdings in SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH – Free Report) by 50.0% in the first quarter, Holdings Channel reports. The firm owned 40,649 shares of the company’s stock after buying an additional 13,551 shares during the quarter. Royal Bank of Canada’s holdings in SPDR S&P Pharmaceuticals ETF were worth $2,199,000 as of its most recent SEC filing.
Several other hedge funds have also recently modified their holdings of the business. Turtle Creek Wealth Advisors LLC purchased a new position in shares of SPDR S&P Pharmaceuticals ETF in the first quarter worth $26,000. Advisory Services Network LLC purchased a new stake in shares of SPDR S&P Pharmaceuticals ETF during the third quarter valued at $34,000. Fifth Third Bancorp purchased a new stake in shares of SPDR S&P Pharmaceuticals ETF during the first quarter valued at $39,000. Kestra Advisory Services LLC bought a new stake in SPDR S&P Pharmaceuticals ETF in the 4th quarter worth about $151,000. Finally, Vista Investment Management bought a new stake in SPDR S&P Pharmaceuticals ETF in the 4th quarter worth about $223,000.
SPDR S&P Pharmaceuticals ETF Stock Performance
Shares of NYSEARCA:XPH opened at $70.42 on Tuesday. SPDR S&P Pharmaceuticals ETF has a fifty-two week low of $45.80 and a fifty-two week high of $71.13. The business has a 50-day simple moving average of $66.59 and a two-hundred day simple moving average of $60.05. The firm has a market cap of $507.02 million, a price-to-earnings ratio of 14.28 and a beta of 0.58.
About SPDR S&P Pharmaceuticals ETF
SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Recommended Stories
- Five stocks we like better than SPDR S&P Pharmaceuticals ETF
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Want to see what other hedge funds are holding XPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH – Free Report).
Receive News & Ratings for SPDR S&P Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
